The United Kingdom and the United States have concluded a major commercial pact that will preserve zero tariffs on British drug shipments going into the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to boost funding on pharmaceuticals through the public health system. This pledge ensures that duties on these crucial products will remain at nothing for a period of the next three years.
This agreement comes after previous threats to dramatically increase duties on patented drug imports, with potential rates discussed up to 100%.
"This deal with the Britain reinforces the international landscape for cutting-edge drugs and brings much-needed balance to American-British pharmaceutical trade," a statement declared.
Commercial Importance
Pharmaceuticals represent one of the the United Kingdom's largest exports to the America, which is by far the biggest buyer for major companies like GSK and AstraZeneca.
Trade data show that in the 12 months leading up to September, the UK exported drugs totaling over eleven billion pounds to the US. This amount accounted for nearly one-fifth of British export trade in that period.
"This guarantee safeguards employment, boosts investment and sets the stage for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary commented.
Key British Pledges
The agreement involves several notable commitments from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new therapies to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to raise overall NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to control costs will be restricted at fifteen percent. Last year, refunds were more than 20%.
Broader Context
This agreement follows a long-running row between the drug companies and the ministers over drug pricing and NHS adoption.
These tensions were exacerbated by arguments that American consumers were paying significantly more for the equivalent treatments than people in the other developed nations.
Recently, several significant drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been pledged toward US facilities.
A senior figure publicly accepted that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had declined as a proportion of its total funding over the last ten years.
